Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.

Wainberg ZA, Soares HP, Patel R, DiCarlo B, Park DJ, Liem A, Wang HJ, Yonemoto L, Martinez D, Laux I, Brennan M, Hecht JR.

Cancer Chemother Pharmacol. 2015 Jul;76(1):61-7. doi: 10.1007/s00280-015-2744-5. Epub 2015 May 13.

PMID:
25969130
2.

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.

Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS.

Cancer. 2012 Dec 1;118(23):5903-11. doi: 10.1002/cncr.27575. Epub 2012 May 17.

3.

Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.

Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D.

Clin Cancer Res. 2007 Apr 1;13(7):1979-86.

4.
5.

Epithelial membrane protein-1 is a biomarker of gefitinib resistance.

Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, Agus DB.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11858-63. Epub 2005 Aug 8.

6.

The flotillins are integral membrane proteins in lipid rafts that contain TCR-associated signaling components: implications for T-cell activation.

Slaughter N, Laux I, Tu X, Whitelegge J, Zhu X, Effros R, Bickel P, Nel A.

Clin Immunol. 2003 Aug;108(2):138-51.

PMID:
12921760
7.
9.

Supplemental Content

Support Center